{"id":"idp-118-lotion","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IDP-118 contains a potent corticosteroid formulated as a lotion for topical application. It works by binding to glucocorticoid receptors in skin cells, reducing inflammatory cytokine production and suppressing local immune cell activity. This mechanism makes it effective for inflammatory skin conditions characterized by erythema, pruritus, and scaling.","oneSentence":"IDP-118 Lotion is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:31.984Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Plaque psoriasis"},{"name":"Other inflammatory dermatoses"}]},"trialDetails":[{"nctId":"NCT05608499","phase":"PHASE3","title":"Duobrii Treatment of Acne Keloidalis Nuchae (AKN)","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-10-26","conditions":"Acne Keloidalis Nuchae, AKN","enrollment":15},{"nctId":"NCT03988439","phase":"PHASE4","title":"A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-03-24","conditions":"Psoriasis","enrollment":45},{"nctId":"NCT05203315","phase":"PHASE3","title":"Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults","status":"COMPLETED","sponsor":"Austin Institute for Clinical Research","startDate":"2022-01-13","conditions":"Plaque Psoriasis","enrollment":21},{"nctId":"NCT05872256","phase":"PHASE4","title":"A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-06-01","conditions":"Scalp Psoriasis","enrollment":20},{"nctId":"NCT06042647","phase":"PHASE4","title":"Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-07-13","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT04720105","phase":"PHASE4","title":"Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-11-19","conditions":"Palmoplantar Psoriasis, Plaque Psoriasis","enrollment":22},{"nctId":"NCT05282771","phase":"EARLY_PHASE1","title":"A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2021-04-16","conditions":"Plaque Psoriasis","enrollment":402},{"nctId":"NCT02045277","phase":"PHASE2","title":"Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2014-02","conditions":"Plaque Psoriasis","enrollment":212},{"nctId":"NCT02462070","phase":"PHASE3","title":"Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-08-11","conditions":"Plaque Psoriasis","enrollment":203},{"nctId":"NCT02785159","phase":"PHASE2","title":"Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-02","conditions":"Psoriasis","enrollment":152},{"nctId":"NCT02785172","phase":"PHASE2","title":"Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-04","conditions":"Psoriasis","enrollment":154},{"nctId":"NCT02462122","phase":"PHASE3","title":"Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-08-19","conditions":"Plaque Psoriasis","enrollment":215},{"nctId":"NCT02462083","phase":"PHASE3","title":"Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-08-11","conditions":"Plaque Psoriasis","enrollment":555},{"nctId":"NCT03058744","phase":"PHASE1","title":"Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-04","conditions":"Psoriasis","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lotion"],"phase":"marketed","status":"active","brandName":"IDP-118 Lotion","genericName":"IDP-118 Lotion","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDP-118 Lotion is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin. Used for Atopic dermatitis, Plaque psoriasis, Other inflammatory dermatoses.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}